Marina Publishes Data from Bladder Cancer Program Showing 'Significant' Tumor Reduction with UsiRNAs
March 10, 2011
Marina Publishes Data from Bladder Cancer Program Showing 'Significant' Tumor Reduction with UsiRNAs
The paper comes out about a month after Marina exclusively licensed the program to Switzerland's Debiopharm, which is responsible for all related development and commercialization activities, for up to $25 million, plus royalties.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Debiopharm Drops Out of Bladder Cancer Deal with Cash-Strapped Marina
November 15, 2012 / Gene Silencing News - Marina Inks Partnership for Bladder Cancer Program
February 3, 2011 / Gene Silencing News - Marina Pipeline on Track with FAP Trial in 2010, But Could Miss Partnership Guidance
November 18, 2010 / Gene Silencing News - Marina Defaults on Loan as Bankruptcy Looms
January 31, 2013 / Gene Silencing News - Marina Extends Cash Runway to Year End, Sells Off Equipment
December 13, 2012 / Gene Silencing News